The Cystatin C Human Elisa Kit Market is projected to grow from USD 800 million in 2025 to USD 1.5 billion by 2035, registering a CAGR of 5.9% during 2026–2035. Rising chronic kidney disease prevalence and increasing demand for accurate renal-function assessment are supporting market expansion.
Cystatin C is increasingly used as a biomarker for evaluating kidney function, creating demand for reliable laboratory testing solutions. Improvements in assay sensitivity, specificity, and throughput are helping laboratories perform more efficient and consistent measurements.
By application, the market includes nephrology, cardiology, and diabetes. Nephrology represented the largest application segment, valued at USD 350 million in 2024 and projected to reach USD 650 million by 2035, supported by the growing need for kidney-function monitoring and early detection of renal disorders.
Research laboratories, clinical laboratories, and pharmaceutical companies represent the principal end users. Increasing research activity, diagnostic testing requirements, and pharmaceutical R&D are creating opportunities for ELISA kit suppliers, while automation and personalized medicine are influencing future product development.
